UK markets closed

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.06+0.49 (+2.38%)
At close: 04:00PM EDT
21.06 0.00 (0.00%)
After hours: 05:32PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.79B
Enterprise value 1.21B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.23
Enterprise value/revenue 7.85
Enterprise value/EBITDA -5.80

Trading information

Stock price history

Beta (5Y monthly) 0.98
52-week change 30.10%
S&P500 52-week change 322.36%
52-week high 325.34
52-week low 311.22
50-day moving average 322.64
200-day moving average 319.07

Share statistics

Avg vol (3-month) 31.09M
Avg vol (10-day) 3882.51k
Shares outstanding 584.98M
Implied shares outstanding 685.89M
Float 884.63M
% held by insiders 10.82%
% held by institutions 1106.46%
Shares short (15 Apr 2024) 49.6M
Short ratio (15 Apr 2024) 48.36
Short % of float (15 Apr 2024) 411.39%
Short % of shares outstanding (15 Apr 2024) 411.30%
Shares short (prior month 15 Mar 2024) 48.33M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.89%
Return on equity (ttm)-40.99%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -229.94M
Net income avi to common (ttm)-209.36M
Diluted EPS (ttm)-2.98
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)577.58M
Total cash per share (mrq)6.8
Total debt (mrq)1.64M
Total debt/equity (mrq)0.29%
Current ratio (mrq)10.00
Book value per share (mrq)6.53

Cash flow statement

Operating cash flow (ttm)-160.6M
Levered free cash flow (ttm)-82.37M